We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has approved Shire’s Gaucher’s disease treatment Vpriv in response to a continuing shortage of Genzyme’s Cerezyme to treat the rare genetic disorder.